Background Psychosocial and behavioral interventions trials targeting a broad range of complex social and behavioral problems such as smoking, obesity and family caregiving have proliferated in the past 30 years. At the same time the use of Data and Safety Monitoring Boards (DSMBs) to monitor the progress and quality of intervention trials and the safety of study participants has increased substantially. Most of the existing literature and guidelines for safety monitoring and reporting of adverse events focuses on medical interventions. Consequently, there is little guidance for investigators conducting social and behavior trials. Purpose This paper summarizes how issues associated with safety monitoring and adverse event reporting were handled in the Resources for Enhancing Alzheimer's Caregiver Health (REACH 11) program, a multi-site randomized clinical trial, funded by the National Institutes on Aging (NIA) and the National Institutes of Nursing Research (NINR), that tested the efficacy of a multicomponent social/behavioral intervention for caregivers of persons with Alzheimer's disease. Methods A task force was formed to define adverse events for the trial and protocols for reporting and resolving events that occurred. The task force conducted a review of existing polices and protocols for data and safety monitoring and adverse event reporting and identified potential risks particular to the study population. An informal survey regarding data and safety monitoring procedures with investigators on psychosocial intervention trials was also conducted. Results Two categories of events were defined for both caregivers and patients; adverse events and safety alerts. A distinction was also made between events detected at baseline assessment and those detected post-randomization. Standardized protocols were also developed for the reporting and resolution of events that occurred and training of study personnel. Results from the informal survey indicated wide variability in practices for data safety and monitoring across psychosocial intervention trials. Conclusions Overall, the REACH 11 experience demonstrates that existing guidelines regarding safety monitoring and adverse event reporting pose unique challenges for social/behavioral intervention trials. Challenges encountered in the REACH 11 program included defining and classifying adverse events, defining "resolution" of adverse events and attributing causes for events that occurred. These challenges are highlighted and recommendations for addressing them in future studies are discussed.
Introduction
During the past 30 years, psychosocial and behavioral interventions designed to maintain and improve health and quality-of-life have proliferated. Researchers have targeted a broad range of complex social and behavioral problemns such as smoking, obesity, m.edical compliance and family caregiving. Recently, there has also been a growing demand for evidence-based practice. Clinicians, social agencies and policy makers iincreasingly require evidence about real-world effects of treatments when mnaking decisions about investing in intervention programs. In response, the randoimized clinical trial (RCT) design, recognized as the gold standard for evaluating medical interventions, is commonly used to evaluate the effectiveness of behavioral intervention approaches.
'ro ensure that RC'I s Tneet tlhe highest scientific standards, many aspects of the design and cornduct of a clinical trial such as participant recruitment, treatnment adherenice, interventioni outcomes and participant safety must be carefully -monitored.
T'oward this enid, the use of independent Data and Safety Monitoring Boards (DSMBs) to monitor the progress and quality of a trial and participant safety has increased substantially 11,21. In fact, in an effort to improve the quality of clinical research and ensure the protection of humansubjects, tlhe National Institutes of I-lealth (NIl I) lhas issued guidelines anid regulations to irncrease the use of data and safety mornitoring within clinlical trials. It is now the policy of NIt-h that each Institute and Center should have a system for th-e appropriate oversight and monitoring of the con-iduct of clinical trials to ensure the safety of the participants and the validity and integrity of the data. A DSMB is required for all Phase III multisite clinical trials involving potential risks to participanits and nmay be required for Phase I or II trials, and even smaller intervention studies if the study population is vulnerable or other study characteristics support the need for an external board 131. 'The Federal L)rug Administration (FDA) has also recently issued draft guidelines on the formation and responsibilities of DSMBs for trials subject to FDA oversight. 'Theses guidelines are fairly conisistent withl procedures followed for NIH-funded trials 141.
The primary role of a DSMB is to enisure the safety of trial participants, through review of adverse events. A key secondalry role is to preserve the quality and credibility of the trial in order to provide reliable results to clinical andi policy communities. Although there is general agreement about the basic roles of D)SMB's, how they are uised and function varies widely across t-ials arnd sporisoring agencies [51. Many issues stuc-h as determiination of when, DSMBs are needed, methods for conductirng interim ( data analyses and confidentiality of interim results remain controversial [6, 7] . For exainple, questions often arise about policies used to guide decisions about the safety and efficacy of trials. Although a number of statistical approaches are available for assessing interim data these statistical procedures in and of themselves are seldom sufficient for making recommendations about trial termination and continuation. Ihere are several cases reported in the literature where strict adherence to the stopping rules established for a trial would have led to less than optimal conclusions about the potential benefits or harm of a treatment 16, 8, 91 . A related controversy is whether access to interimn outcome data should be restricted to DSMB members. 'I he rationale for masking is preservation of trial initegrity and credibility and protection from bias. ArguLments for unmasking are based on the premise that excluding trial members from access to interim ouLtcomes may result in erroneous conclusions about treatment effects as DSMB members may not have access to key information they need to interpret the results of the interim analysis. Clearly safety monitoring can mean different thinlgs to differen-t people, depending on their relationship to a particular study.
Controversies also exist regarding the definition and reportinrg of adverse events. Adverse events are generally defined as any unfavorable or unLintended symptom, sign or disease associated with a medical treatment or procedure that may or may not be related to the treatment or procedure [10] . lnivestigators are typically required to report all AEs anid assess severity whether or not they are related to sttucdy treatments. tn principle, the term adverse even.t should be noin-judgeml-ental with regard to the relationship between treatment and the event. AEs can be associated withl the treatment, the disorder or behavior being targeted, a concurrent disorderor treatment, or it may be entirely unrelated.
Existinig gLuidelines for the definitioins and reporting of AEs are somewhat broad and vague. The current FDA guideline req-uires reporting of AEs tlhat are "serious and unexpected" whereas the NIH requires reporting of "unanticipated problems" posing risks to study participants [ 1] . Clearly, there can be considerable variability in the interpretation of terrms such as "serious", "unexpected" and "unanticipated". Furthermore, existing policies offer little guidance regarding required docunmentation and protocols for reporting. Support for this view can be found in recent reviews of the AE liter-atLire which have demonstrated fairly wide variance in the ter-ms ulsed to describe adverse events (eg, adverse events versus side effects versus complications) as well as variations, even within trials, in AE reporting, especially with respect to judgements of severity or relatedness [12, 13] . Consistency in AE Clinical Trials 2006; 3: 107-118 www.SCTiournal.com documentation, characterization and evaluatiorn is importaint since lack of consistency can ultiinatelv affect decisions about treatment adoption. Judgements of causality mtust also take into account the complex dynamic interplay betw-een the inherent risks of the intervention and contextual factors such as comorbidities related to a disease that can influence the type and frequencv of AEs that occur within a trial. Lack of understanding of these factors and their potential relationship to stuLdy treatments can lead to biasirng in data reporting and interpretation as well as poor decisions abotut when to stop a trial.
Issues surrounding safety monitoring and AE reporting are even more complex for social and behavioral intervention trials. Because most of the existing literature regarding AEs is based on medical interventions, there exists little guidance for inivestigators conducting social and behavior trials. To help fill this gap, this paper reports hlow issues associated with safety monitoring and reporting of adverse events were} handled in the Resources for Enhancing Alzheimer's Caregiver 1--lealth (REACI-I 11) program. Data are also reported from an informal survey conducted with investigators of other currently active psychosocial intervention trials regarding data and safety monitoring procedures.
The overall goal of the paper is to idenitify the challenges of applying existing gutidelinies for monitoring clinical trials for safety to social/behavioral intervention trials and to make suggestions as to how they might be addressed in future studies.
Overview of the REACH If program
REACI-h 1I was a multisite randomlized clin.ical trial, funded by the National Institutes on Aging (NA) and the National Institutes of Nursing Research (NINR) that tested the efficacy of a multicomponent social/behavioral intervention for caregivers of persons with Alzheimer's disease. The randoimized cohort consisted of 212 Hispanic/Latino, 219 white Caucasian, and 211 black/African-American caregivers recrulited from five sites in the US: Birmingham, AL; Miami, FL; Memphis, TN; Palo Alto, CA; Philadelphia, PA. The studly also incltuded a coordinating center at the University of Pittsburgh.
Eligibility
Eligibility criteria for caregivers included being Hispanic/Latino, white/Caucasian, or black/African-American; being over the age of 21; living with or sharing cooking facilities with the patient; providing care for a relative with Alzheimer's Disease andi Related Disorders (AI)RD) for a minimum of four hours per day for at least the past six months; caring for a patieint withi memory or behavior problems, and feeling overwhelmed, or angry, or having crying spells, or feeling CUt off from family or friend's because of caregiving demands. Caregivers were excluded if they were involved in another caregiver intervention study, participated in the earlier REACt-I I trial, or had an illness that would prevent them from participating for at least six mnontlis. Other requirements were logistical and included havin-g a telephone, planning to remain in the geographic area for at least six months, and competency in either Englishi or Spanish.
In order to be eligible for the study, caregivers lhad to confirmi that their relative had a diagnosis of 
Protocol
Participants were screened for eligibility, given a baseline assessment, and subsequently randomized to treatment or control condition within each of the three ethnic groups. Caregivers were assessed a second tirne six months later after the intervention was completed. Ihe intervention was designed to improve the quality of life of caregivers in multiple doimains. Therefore, the primary outcome was a mUltivariate quality of life indicator that assessed caregiver burden, depressive symptoms, self-care, social sLupport, and patient problem behaviors. In addition, caregiver clinical depression and patient institutional placement were assessed.
Study design
The design of the intervention was guided by consideration of the existing literature and findings from the multisite REACH I [15, 16] . The evidence from both sources indicated that caregiving presents multiple challenges and that there is no single, consistently effective method for achieving clinical significarnce effects among caregivers. As a result, the interverntion was based on a risk appraisal approach and five areas linked to caregiver stress health processes: burden, depression, self-care, social support and care recipient problem behaviors [17] were matched to five corresponding intervention comnponents. Because there is considerable variability in the needs of caregiver/care recipients, a struLctured risk appraisal was administered at baseline and dosing was adjusted to level of risk presen-t within each area. For example, a person www.SCTjournal.com who had minimal problemTs with depression would only receive a smiall dose of the interventionr. component designed to improve emotional wellbeing. To deliver the interveintion in a cost effectiv-e manner the intervention was administered ulsing a combination of in-home visits aulgmented by telephone/computer technology in 12 sessions over six months. In addition, five telephone administered cross-site support group sessions were available to intervention arm participants. Caregivers were also provided with a Caregiver Notebook that contained basic ediucationial materials as well as other instructional inaterials provided by the interventionist during the home sessions.
In contrast, caregivers in the conitrol ar-m received a packet of basic educational materials aind two brief (<15 minute) telephone "check-in calls" at three and five months post randomization. They were also invited to participate in a workshop on dementia and caregiving following the six-month assessment. All materials were available in English and Spanish.
Overview of safety monitoring in REACH 11
Because REACH TI was a multisite intervention trial and involved a vulnerable population (caregivers and dementia patients) an independeint DSMB was required by the sponsoring agencies. The memnbers of the DSMB were identified by the sponsoring agencies, with recommendations from the Trial Steering Committee, prior to the start of the study. The five members included experts in interventioll research, caregiving, biostatistics, and ethics. 'Ihe primary responsibilities of the l)SMBI included monitoring of participant recruitmeint anid safety, protocol compliance, and data quality. 'The DS1MB met twice yearly; once in person and onice bv coniference call. They received data reports a month prior to each meeting that contained informatioin about participant recruitment, retention, participant characteristics and adverse events. In addition to the DSMB members meeting attendees included the program officers from the NIA and the NINR, the study statistician, the Principal Investigator of the Coordinating Center and the Chair of the REACH 1-I Steering Committee.
At the initial mneetinig, the DSMB reviewed the study protocol (eg, informed consent forms, intervention protocols, data collectioni instruments), and agreed upon data reporting requirements (frequency, type of data and reporting format).
They also reviewed the definitions of adverse events and protocols for resolution of those events adopted for the trial (Table 1) . At subsequient meetings the DSMB reviewed the progress of the study (eg, recruitmnenit by race/ethnicity at each site, protocol deviationis, intervention adherence, adverse events, site visit sunmmaries, data quality, attrition, effectiveness of randomization procedures) and made recommendations concerning its continuation. The decisions of the DSMB were considered advisory to the NIH. Formal stopping rules were not specified for the trial. The DSMB worked with the Coordinating Center and the program officers to choose a monitoring apprcoach that best suited the study. An interim data anialysis, perforrned by the trial statistician, was also conducted. Tob avoid potential bias, all site investigators aind the lPl of the Coordinating Center were mlasked to the results of the interim analvses. 'I he Coordinating Ceniter generated minutes for each of the DSMB meetings which were thein submitted to the NIA, NINR and the sites who then distributed the minuLtes to the local Institutional Review Boards (IRB).
Challenges encountered in the REACH 11 program Defining and classifying adverse events (AEs) One of the initial challenges faced by the REACH 11 investigators was defining and classifying AEs for the trial. To facilitate this process a task force with representatives from each of the five sites, the coordinating ceniter, and the sponsoring agencies was formed. Given that this was a multisite trial, it was important to ensure that the definition of AEs was standardized across the five intervention sites.
In additioii, as the focus of the trial was the dyad, A}Es needed to be defined for both the caregiver and the care recipient.
Also, the intervention was based on a risk appraisal apprcoachl and a baseline assessment, whlich inClUded mleaSuires of depression, quality of care, care recipient problem behaviors was administered prior to randomization. Thus, AEs and potential risks to the participants could be detected prior to the start of the intervention. For example, the risk appraisal quLestionnaire asked caregivers if the care recipient had threatened to harm him or herself or others, had access to a gun or was still drivinlg. Although, events detected at baseline could not be attributable to the intervention, because of ethical aind lRB requiremenits they needed to be reported and addressed. Consideration also needed to be given to the characteristics of the participant population and contextual factors surrounding the caregiving situLation.. For example, dementia patients are likely to be elderly and have medical or behavioral comorbidities such as wandering or aggression. Likewise, it is not uncommon for The CG was advised to monitor advised to monitor the patient and the patient and if the situation if the situation persists to contact persists to contact their their primary care physician primary care physician Care recipient has The P1 or desigriee (eg, clinical Care recipient has access The PI or designee (eg, clinical access to a gun supervisor, project coordinator) to a gun supervisor, project coordinator) contacted the caregiver to contacted the caregiver to discuss discuss the safety implications the safety implications and devise and devise a plan of action a plan of action to block the care to block the care recipient's recipient's access to the gun. If the access to the gun. If the CG CG refused or was unable to block refused or was unable to block the CR's access Adult Protective the CR's access Adult Protective Services may have been contacted.
Services mray have been
If it appeared that the assessor or contacted. If it appears that interventionist was in danger the an assessor or interventionist CGs/CR's participation in the study was in danger the CGs/CR's was terminated (unless it was the participation in the study six-month follow-up) was terminated www.SCTjournal.com Data safety monitoring in behavioral trials 11 3 supervisor, project coordinator) supervisor, project coordinator) contacted the caregiver to contacted the caregiver to determirie the nature of the determine the nature of the situation and devise a plan situation and devise a plan of action. of action. If the caregiver If the caregiver refused or was not refused or was not able to able to able to control the situation able to control the situation Adult Protective Services may have Aduilt Protective Services mnay been contacted by the site have been contacted by the site aResolution means that the problem has been addressed with the caregiver; where appropriate (eg, CR driving; access to a gun) and a plan of action and recommendations are discussed and no further action by the research team is required. bResolution of baseline adverse events was considered as not applicable due to the fact that the intervention had not yet begun, therefore there was no concern about event being caused by intervention and the occurrence of this type of event at baseline would have precluded the dyad from being randomized in the trial.
cSevere medical problem is defined as arn illness (rnedical or emotional) or injury that impairs a person's daily functioning or causes high levels of subjective distress. Examples might incluLde: urinary tract infection, chrornic cough, flu, broken limb (resulting from a fall). caregivers to suffer fromii depressive syrniptorris. While these types of events do not fall unider tihe standard definition of serious Als they still pose a potential risk to the individual. Finally, as noted, the population was ethnically diverse and events such as institutionalization of the patient tend to be more common among some caregiver populations (eg, non-Hispanic whites) as opposed to others (eg,
Hispanics/Latinos) [181.
Based on these considerations, we distiinguished among two categories of events: adverse events and safety alerts. Ihe definition c)f "adverse event" was consistent with traditional definitions of AEs and included events such as death, hospitalization and emergency room visits. "Safetv alerts" were events that were relevant to the study Populationi and posed safety risks to study participants. Examples of safety alerts included caregivers having symptoms of depression or the care recipienlt diriving (Table 1) . A distinction was also made betweeni events that were detected at baseline (baselin-e adverse events and baseline safety alerts) versus those that occurred following randomization and the six-month followup assessment (adverse events and safety alerts).
Defining "resolution"
A second task involved defining what constituted "resolution" of a safety alert or an adverse event.
This task was challenging as events such as institutionalization are comiimon among dementia patients and often permanent. For example, a question arose regarding resolutionof patient institutionalization. Should resoltution be defined as the return of the patient to the home setting or simply knowledge that placemient occurred and the reason for the placement decision? Obviously, placement of patients who were permanently placed would never be "resolved" if the definition of resolution of this event was the patient returning to home. the final definitions of resolution for AEs and safety alerts are presented in 'Fable 1.
TFhe definlitions of adverse events and safety alerts and protocols for event resolution were submitted to the DSMB for review and approval. An important aspect of this process was educating the DSMB about the nature of the intervention and the characteristics of the target population. Although all of the members of the DSMB had experience with clinical trials and expertise in intervention research some of the members had limited expertise with caregiving and dementia patients. Following approval by the DSMB, study personnel (assessors andc intervelltionists) at the five intervention sites ajnd the Coordinating Center were trained in protocols for identificatiorn, reporting and resolution of AEs and safety alerts. TIhese protocols were also included in the manual of operations. As shown in Table 2 , the most common events among caregivers were evidence of high levels of depressive symptoms. Among care recipients, the most common events were hospitalization, comments related to death, institutionalization and death. Also, as indicated there was some variation in frequency of event according to ethlnicity of the dyad. Institutionalization, access to a gun and continued drivinig was imore coimmon among the white/Cau-Lcasian care recipients as compared to the Hispanic/Latino and black Ainericani care recipients. *CG/CR abuse events did not occur.
Reporting requirements and attribution
Developing a standardized reporting systemn was also complicated given differences in requirements among the site IRBs. Some sites were required to report all events to the local IRB irrespective of event severitv whereas other sites were only required to report AlEs an-d not safety aler-ts. 'lihe DSMB required reporting of all even-ts.
To help ensure consisterncy in reporting across the sites, adverse events and safety alerts were tracked using standardized forms that recorded the date of the event, type of event, attributioni of the event (eg, was it interventiorn related), whether the event was resolved or controlled and the resolution date. These forms were completed by the site PI or designee (eg, clinical supervisor, project coordinator) and faxed to the Coordinating Center within 24 hours of learning of the event. Sites were also reqtlired to complete an Adverse Event Resolution Note which further detailed the specifics of the how the event was addressed.
'lhe issue of attribution proved to be somewhat of a challenge for the REACH 11 fact that dementia patients tend to be elderly andl have other comorbid conditions. In fact, in the REACH 11 trial hospitalizations were the mlost common AE among the care recipients (T'able 2).
Though unlikely to be related to the] interventioni, the relatively high frequency of hospitalizationis generated concern among the memnbers of the DSMB, particularly since more were reported for care recipients in the intervention con(lition than in the control arm ('Fable 3). Because of this concern, the DSMB required further analyses of these events. It was deterrnined that the higher frequency of hospitalizations am.ong care recipients in the intervention conditio-n was likely due to greater contact between the intterventionists and caregiver who received the intervention and not related to the intervention. Similar issues arose for care recipient emergency room visits. The problems associated with determining attribution experienced in the REACI II program highlight the difficulties of applying existing defiinitions of AEs, developed for medical intervention, to social behavioral interventiorn trials. hi addition, this issue underscores the imiportan-ce of ensuring that members of the DSMB understai-nd the niature of the intervention, the disease or behavioral problem of interest and the characteristics of the target population. A lack of understaniding of these factors amonig DSMB members can potentially lead to erroneous decisions abouLt the safety and impact of the in-terveintion.
Results of the informal survey
As rnoted, the authors were interested in ascertaining to what extent the adverse event issues encountered in the REACH 11 Only 78% of the trials had esta'blishied protocols for defining adverse events; 60% had established protocols for reporting the attribuLtion/causality of serious adverse events and 45%Y/ had such protocols for other-than-seriotus events. Als were identified through a variety of souLrces iincluding participant self-report (77%), interventionists interactioni witlh the participant (77%) or standardized questionnaires at schedules assessments (54%). In most studies attribution was determined by the Principal Investigator (85%) or the IRB (67%). Similarly resolution was typically determined by th-e Principal Investigator (64%) orthe IRB (64%).
Key challenges
Investigators were also asked to describe any challenges or problems that arose dluring the trial related to safety monitoring or reporting of adverse events. Commonly reported probleins included definition of what constituted anl adverse event (especially for those trials that included a vulnerable population), determnination of attribution: and lack of consistency in reportinig of AES by study staff. Overall, the list of problems was similar to the challenges faced by the REACH II investigators.
Discussion
In an effort to iimprove the quality of clinical research and ensure the safety of research participants, safety monitoring is becoming an integral component of clinical research projects. Ilotential benefits associated with safety monitoring include early identification of treatm:nernts that pose risk to individuals or which are likely to be ii-neffective, iinformation on the extent to whichi recruited participants reflect the profile anticipated anid overall imnprovements in data quality. Sumimary data on adverse events can also provide useful insights into the needs of study populations and aid in the design of future intervention approaches. Currently however, guidelines for data safety monitoring are somewhat broad and. vary across sponsoring agencies, including agencies within the federal goveriirnenlt. As a result there is wide variability in policies and protocols for conducting data and safety monitorinig and mluch debate surrounding issues related to the use of DSMBs, stopping rules, and definition and reporting of adverse events. Questions regarding safety mnonitoriing are especially complex for social/behavioral intervention trials. This paper describes the protocols adopted for safety, monitoring within the REACH 1I project, a mrultisite randomized clinical trial that evaluated the efficacy of a imulticomponent psychosocial interverntion for caregivers of dementia patients. Unique characteristics of the REACH 11 program iincluded a risk-appraisal based intervention approach, a focus on the dyad, and inclusioin of an ethnlically diverse and vulnerable study population. Challenges that were encountered in developing a plan for safety mnonitoring in the REACH II program included defining and classifying adverse events, defining "resolution" of adverse events and attributing caulses for events that occurred. Results of an informal survey suggest that these problems are not unique and common in other behavioral trials.
On the basis of the REACH I1 experience, the followin-ig is a sunmmnary of recommendations for implemlenting the existing guidelines for safety mnonitoring in social behavioral trials. Our intent is to provide suggestions rather than a prescription as it is recogniized that models for data and safety monitoring vary accordinig to the need and characteristics of a particular trial. Data Data safety monitoring in behavioral trials 11 7 as well as the fornmat and con-tent of DSMBI reports, statistical procedures anid miionitoring guidelines should be clearly established before the start of the trial. Ellenberg and colleagues 171 and the L)Ata MOnitoring Committees: Lessons, Ethics, Statistics (DAMOCLES) study group [20] maintain that intervention trials would benefit from the development of a charter outlining the protocols and responsibilities for data and safety monitoring. Both groups provide examples of such a charter that encompass guidelines for DSMB membership, responIsibilities of the DSMB, protocols ftor the organization of DSMB meetings, data reporting, interim data analyses and decision making and reporting hierarchlies. However, these charters while useful as guidelines are primarily oriented at medical inltervention trials and may need to be adapted for psychosocial interventions. Furthermore, they do niot address the issue of defining adverse events and determining what constitutes "satisfactory" resolutioin of events that occur. We recommend that these proposed charters be considered a reference and perhaps checklist for the issues that rieed to be addressed if a formal DSMB is required for a trial.
If a formal DSMB is requiired, thie cormmiittee must include inidividuals with expertise in the clinical area being studied and the target population. Expertise in both is needed to etnsure appropriate interpretation of adverse events. [or example, in the case of REACH Il having expertise in both caregiving and Alzheimer's Disease was important. Having individuals with some knowledge and experience with clinical trials and data safety monitoring is also valuable. Iln any case, it is essential that all members of a DSMB have a thorough understanding of the interverntionI protocol, the problenm area being addressed and the chalacteTistics of the study population.
However, the size of the coinmittee is also an important consideration as the nunmber of mnembers is likely to have an impact on the quality of the decision process.
Identifying and defining adverse events
Careful consideration also needs to be given defining what constitutes an adverse event for a trial. Defining adverse events, accordiing to criteria developed for medical trials, may not be appropriate for some types of interventions. As clemonstrated in REACH II eve-nts such as hospitalization anid placement are common among patients with dementia and unlikely to be related to behavioral interventions. Reporting these types of events and investigating their causes may place undue bturden on study personnel, DSBM members and local IRBs. A more effective strategv would be to have DSMB www.SCTjournal.com mnemnbers and investigators reach consensus about those adverse events important for assuring the safety and well-being of specific study population enrolled in the study. ''lhese judgements should be based on the types of individuals and problems being studied, the nature of the interventions being tested, as well as the findings from related prior research. Since ascertaining the causes of adverse events can be labor intensive and costly, the focus should be on adverse events that reasonably might be lin.ked to the interverntion.
Protocols for monitoring and reporting adverse events
Protocols also need to be developed for standardized tracking and reporting of adverse events. These protocols need to include delineation of the type of data that needs to be reported (eg, group versus site level data), and the timing and frequency of data reports. Ihis is especially important for multisite trials to ensure consistency in data reporting. Where possible, there should also be consistency in reporting requirements between local IRBs and the sponsoring agencies. This would help minimize duplication of effort and costs associated with data reporting. For example, in the case of REACH 11, differences iri eveent report forms required by local IRZBs and those dev-eloped for the caused a duplication of effort for study personnel. Equally important is inlsuring that study personal are trained in protocols for identifying and reporting adverse events. Criteria also need to be established for assigniing event attribution.
Interim data analysis
Finally, procedures for the interim data analyses need to be clearly established prior to initiating the trial. Important issues that need to be considered iniclude the outcome measures that will be included in the analyses, who will conduct the analyses, who will be included in the discussion of the analysis, andl the extent to which the investigators are masked with respect to study outcomes. With respect to the issue of masking, we recommend that, at minimium, the study statistician be included in the discussion of the results of the interim analyses to ensure that the findings are interpreted appropriately by DSMB members.
Overall, there are a number of issues with data safety monitoring that need to be addressed within clinical trials. These issLues are likely to become imiore salient as the demand for evidence-based treatment and translational research continues to grow. Practices for data and safety monitoring need to achieve an appropriate balance between the Clinical Trias 2006; 3: 107-118 
